1 Age-dependent topic modelling of comorbidities in UK Biobank identifies

2 disease subtypes with differential genetic risk

- 3
- 4 Xilin Jiang^{1,2,3,4,5,6}, Martin Jinye Zhang^{4,7§}, Yidong Zhang^{1,8,9§}, Michael Inouye^{5,6,10,11,12,13}, Chris
- 5 Holmes^{1,2,14}, Alkes L. Price^{4,7,15}*, Gil McVean¹*
- 6

7 Affiliations

- 8 ¹ Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of
- 9 Oxford, Oxford OX3 7LF, UK
- 10 ² Department of Statistics, University of Oxford, Oxford OX1 3LB, UK
- ³ Wellcome Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK
- ⁴ Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA
- 13 ⁵ British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and
- 14 Primary Care, University of Cambridge, Cambridge UK
- ⁶ Heart and Lung Research Institute, University of Cambridge, Cambridge UK
- ⁷ Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge,
- 17 MA, USA
- 18 ⁸ CAMS China Oxford Institute, Nuffield Department of Medicine, University of Oxford,
- 19 Oxford OX3 7BN, UK
- 20 ⁹ Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese
- 21 Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- 22 ¹⁰ Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary
- 23 Care, University of Cambridge, Cambridge, UK.
- 24 ¹¹ Health Data Research UK Cambridge, Wellcome Genome Campus and University of
- 25 Cambridge, Cambridge, UK.
- 26 ¹² British Heart Foundation Cambridge Centre of Research Excellence, Department of Clinical
- 27 Medicine, University of Cambridge, Cambridge, UK.
- 28 ¹³ Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute,
- 29 Melbourne, VIC, Australia.
- 30 ¹⁴ The Alan Turing Institute, London NW1 2DB, UK
- ¹⁵ Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA
 32
- 33 § These authors contributed equally to this work
- 34 *These authors jointly supervised the work
- 35 Corresponding authors:
- 36 xilinjiang@hsph.harvard.edu
- 37 aprice@hsph.harvard.edu
- 38 gil.mcvean@bdi.ox.ac.uk
- 39
- 40

It is made available under a CC-BY 4.0 International license .

41 Abstract

Longitudinal data from electronic health records (EHR) has immense potential to improve 42 clinical diagnoses and personalised medicine, motivating efforts to identify disease subtypes 43 from age-dependent patient comorbidity information. We introduce an age-dependent topic 44 45 modelling (ATM) method that provides a low-rank representation of longitudinal records of hundreds of distinct diseases in large EHR data sets. The model learns, and assigns to each 46 individual, topic weights for several disease topics, each of which reflects a set of diseases that 47 tend to co-occur as a function of age. Simulations show that ATM attains high accuracy in 48 distinguishing distinct age-dependent comorbidity profiles. We applied ATM to 282.957 UK 49 50 Biobank samples, analysing 1,726,144 disease diagnoses spanning 348 diseases with \geq 1,000 incidences. We inferred 10 disease topics optimising model fit. We identified 52 diseases with 51 heterogeneous comorbidity profiles (\geq 500 incidences assigned to each of \geq 2 topics), including 52 breast cancer, type 2 diabetes (T2D), hypertension, and hypercholesterolemia; for most of these 53 54 diseases, topic assignments were highly age-dependent, suggesting differences in disease 55 aetiology for early-onset vs. late-onset disease. We defined subtypes of the 52 heterogeneous diseases based on the topic assignments, and compared genetic risk across subtypes using 56 polygenic risk scores (PRS). We identified 18 disease subtypes whose PRS differed significantly 57 58 from other subtypes of the same disease, including a subtype of T2D characterised by 59 cardiovascular comorbidities and a subtype of asthma characterised by dermatological comorbidities. We further identified specific SNPs underlying these differences. For example, 60 the T2D-associated SNP rs1063192 in the CDKN2B locus has a higher odds ratio in the top 61 62 quartile of cardiovascular topic weight (1.19 ± 0.02) than in the bottom quartile (1.08 ± 0.02) $(P=4 \times 10^{-5}$ for difference). In conclusion, ATM identifies disease subtypes with differential 63 64 genome-wide and locus-specific genetic risk profiles. 65

66

67

68

69

It is made available under a CC-BY 4.0 International license .

71 Introduction

- 72 Longitudinal electronic health record (EHR) data, encompassing diagnoses across hundreds of
- 73 distinct diseases, offers immense potential to improve clinical diagnoses and personalised
- 74 medicine¹. Despite intense interest in both the genetic relationships between distinct diseases²⁻¹¹
- and the genetic relationships between biological subtypes of disease $^{12-15}$, there has been limited
- 76 progress on classifying disease phenotypes into groups of diseases with frequent co-occurrences
- 77 (comorbidities) and leveraging comorbidities to identify disease subtypes. Low-rank modelling
- has appealing theoretical properties 16,17 and has produced promising applications $^{18-24}$ to infer
- 79 meaningful representations of high-dimensional data. In particular, low-rank representation is an
- 80 appealing way to summarise data across hundreds of distinct diseases $^{25-27}$, providing the
- 81 potential to identify patient-level comorbidity patterns and distinguish disease subtypes. Disease
- 82 subtypes inferred from EHR data could be validated by comparing genetic profiles across
- 83 subtypes, which is possible with emerging data sets that link genetic data with EHR data²⁸⁻³¹.
- 84

85 Previous studies have used low-rank representation to identify shared genetic components^{25–27}

- 86 across multiple distinct diseases, identifying relationships between diseases and generating
- 87 valuable biological insights. However, age at diagnosis information in longitudinal EHR data has
- the potential to improve such efforts. For example, a recent study used longitudinal disease
- 89 trajectories to identify disease pairs with statistically significant directionality³², suggesting that
- 90 age information could be leveraged to infer comorbidity profiles that capture temporal
- 91 information. In addition, patient-level comorbidity information could potentially be leveraged to
- 92 identify biological subtypes of disease, complementing its application to increase power for
- 93 identifying genetic associations¹² and to cluster disease-associated variants into biological
- 94 pathways⁸; disease subtypes are fundamental to disease $aetiology^{14,33-36}$.
- 95

96 Here, we propose an age-dependent topic modelling (ATM) method to provide a low-rank

- 97 representation of longitudinal disease records. ATM learns, and assigns to each individual, topic
- 98 weights for several disease topics, each of which reflects a set of diseases that tend to co-occur as
- 99 a function of age. We applied ATM to 1.7 million disease diagnoses spanning 348 diseases in the
- 100 UK Biobank, inferring 10 disease topics. We identified 52 diseases with heterogeneous
- 101 comorbidity profiles that enabled us to define disease subtypes. We used genetic data to validate
- 102 the disease subtypes, showing that they exhibit differential genome-wide and locus-specific
- 103 genetic risk profiles.
- 104
- 105

It is made available under a CC-BY 4.0 International license .

106 Results

107 *Overview of methods*

108 We propose an age-dependent topic modelling (ATM) model, providing a low-rank

109 representation of longitudinal records of hundreds of distinct diseases in large EHR data sets

110 (Figure 1, Methods). The model assigns to each individual *topic weights* for several *disease*

- 111 *topics*; each disease topic reflects a set of diseases that tend to co-occur as a function of age,
- 112 quantified by age-dependent *topic loadings* for each disease. The model assumes that for each
- disease diagnosis, a topic is sampled based on the individual's topic weights (which sum to 1
- across topics, for a given individual), and a disease is sampled based on the individual's age and
- the age-dependent topic loadings (which sum to 1 across diseases, for a given topic at a given
- age). The model generalises the latent dirichlet allocation (LDA) model^{37,38} by allowing topic
- 117 loadings for each topic to vary with age (Supplementary Note, Supplementary Figure 1).
- 118

119 We developed a method to fit this model that addresses several challenges inherent to large EHR

120 data sets; the method estimates topic weights for each individual, topic loadings for each disease,

121 and posterior diagnosis-specific topic probabilities for each disease diagnosis. First, we derived a

- scalable deterministic method that uses numerical approximation approaches to fit the
- 123 parameters of the model, addressing the challenge of computational cost. Second, we used the
- 124 prediction odds ratio³⁹ to compare model structures (e.g. number of topics and parametric form
- of topic loadings as a function of age), addressing the challenge of appropriate model selection;
- 126 roughly, the prediction odds ratio quantifies the accuracy of correctly predicting disease
- 127 diagnoses in held-out patients using comorbidity information, compared to a predictor based
- 128 only on prevalence (see Methods and Supplementary Table 1). Third, we employed collapsed
- 129 variational inference⁴⁰, addressing the challenge of sparsity in the data (e.g. in UK Biobank data
- that we analysed, the average patient has diagnoses for 6 of 348 diseases analysed); collapsed
- 131 variational inference outperformed mean-field variational inference³⁷ in empirical data. Further
- details are provided in the Methods section and Supplementary Note; we have publicly released
- 133 open-source software implementing the method (see Code Availability).
- 134

135 We applied ATM to longitudinal records of 282,957 individuals from the UK Biobank²⁹,

136 containing a total of 1,726,144 disease diagnoses spanning 348 diseases (see Data Availability).

137 Each disease diagnosis had an associated age at diagnosis, defined as the earliest age of reported

138 diagnosis of the disease in that individual; we caution that age at diagnosis may differ from age

- 139 at disease onset (see Discussion). ATM does not use genetic data, but we used genetic data to
- 140 validate the inferred topics (Methods).
- 141
- 142 Simulations

143 We performed simulations to compare ATM with latent dirichlet allocation (LDA)^{37,38}, a simpler

- topic modelling approach that does not model age. We simulated 61,000 disease diagnoses
- spanning 20 diseases in 10,000 individuals, using the ATM generative model; the average

It is made available under a CC-BY 4.0 International license .

number of disease diagnoses per individual (6.1), ratio of #individuals/#diseases (500), topic

- 147 loadings, and standard deviation in age at diagnosis (8.5 years for each disease) were chosen to
- 148 match empirical UK Biobank data. We assigned each disease diagnosis to one of two subtypes
- 149 for the underlying disease based on age and other subtype differences, considering high,
- 150 medium, or low age-dependent effects by specifying an average difference of 20, 10, or 5 years
- respectively in age at diagnosis for the two subtypes. For each level of age-dependent effects,
- we varied the proportion of diagnoses belonging to the first subtype (*subtype sample size*
- *proportion*) from 10-50%. Further details of the simulation framework are provided in the
- 154 Methods section. Our primary metric for evaluating the LDA and ATM methods was area under 155 the precision-recall curve (AUPRC)⁴¹, where precision is defined as the proportion of disease
- diagnoses that a given method assigned to the first subtype that were assigned correctly and
- recall is defined as the proportion of disease diagnoses truly belonging to the first subtype that
- 158 were assigned correctly. We discretized the subtype assigned to each disease diagnosis by a
- 159 given method by assigning the subtype with higher inferred probability. We note that AUPRC is
- 160 larger when classifying the smaller subtype; results using the second subtype as the classification
- 161 target are also provided. We used AUPRC (instead of prediction odds ratio) in our simulations
- 162 because the underlying truth is known. Further details and justifications of metrics used in this
- 163 study are provided in the Methods section and Supplementary Table 1.
- 164

165 In simulations with high age-dependent effects, ATM attained much higher AUPRC than LDA

- across all values of subtype sample size proportion (AUPRC difference: 24%-42%), with both
- 167 methods performing better at more balanced ratios (Figure 2, Supplementary Table 2).
- 168 Accordingly, ATM attained both higher precision and higher recall than LDA (Supplementary
- 169 Figure 2). Results were qualitatively similar when using the second subtype as the classification
- target (Supplementary Figure 3). In simulations with medium or low age-dependent effects,
- 171 ATM continued to outperform LDA but with smaller differences between the methods. In
- 172 simulations without age-dependent effects, ATM slightly underperformed LDA (Supplementary
- 173 Figure 4A).

174

175 We performed three secondary analyses. First, we varied the number of individuals, number of 176 diseases, or number of disease diagnoses per individual. ATM continued to outperform LDA in 177 each case, although increasing the number of individuals or the number of disease diagnoses per 178 individual did not always increase AUPRC (Supplementary Figure 4B). Second, we performed 179 simulations in which we increased the number of subtypes from two to five and changed the 180 number of diseases to 50, and compared ATM models trained using different numbers of topics 181 (in 80% training data) by computing the prediction odds ratio; we used the prediction odds ratio 182 (instead of AUPRC) in this analysis both because it is a better metric to evaluate the overall 183 model fit to the data, and because it is unclear how to compare AUPRC across scenarios of 184 varying topic numbers (see Supplementary Table 1). We confirmed that the prediction odds 185 ratio was maximised using five topics, validating the use of the prediction odds ratio for model

It is made available under a CC-BY 4.0 International license .

186 selection (Supplementary Figure 5A). Third, we computed the accuracy of inferred topic

- 187 loadings, topic weights, and grouping accuracy (defined as proportion of pairs of diseases truly
- 188 belonging to the same topic that ATM correctly assigned to the same topic), varying the number
- 189 of individuals and number of diseases diagnoses per individual. We determined that ATM also
- 190 performed well under these metrics (Supplementary Figure 5B-E).
- 191

We conclude that ATM (which models age) assigns disease diagnoses to subtypes with higheraccuracy than LDA (which does not model age) in simulations with age-dependent effects. We

194 caution that our simulations largely represent a best-case scenario for ATM given that the

- 195 generative model and inference model are very similar (although there are some differences, e.g.196 topic loadings were generated using a model different from the inference model), thus it is important
- 197 to analyse empirical data to validate the method.
- 198

199 Age-dependent disease topic loadings capture comorbidity profiles in the UK Biobank

200 We applied ATM to longitudinal records of 282,957 individuals from the UK Biobank²⁹. We

used Phecode⁴² to define 1,726,144 disease diagnoses spanning 348 diseases with at least 1,000
diagnoses each; the average individual had 6.1 disease diagnoses, and the average disease had a
standard deviation of 8.5 years in age at diagnosis. The optimal ATM model structure included
10 topics and modelled age-dependent topic loadings for each disease as a spline function with
one knot (see below). We assigned names (and corresponding acronyms) to each of the 10
inferred topics based on the Phecode systems⁴² assigned to diseases with high topic loadings

207 (aggregated across ages) for that topic (Table 1, Supplementary Table 3).

208

209 Age-dependent topic loadings across all 10 topics and 348 diseases (stratified into Phecode

systems), summarised as averages across age < 60 and age ≥ 60 , are reported in Figure 3,

211 Supplementary Figure 6, and Supplementary Table 4. Some topics such as NRI span diseases

across the majority of Phecode systems, while other topics such as ARP are concentrated in a

213 single Phecode system. Conversely, a single Phecode system may be split across multiple topics,

e.g. the digestive system is split across UGI, LGI, and MDS. We note that topic loadings in

215 diseases that span multiple topics are heavily age-dependent. For example, type 2 diabetes

216 patients assigned to the CVD topic are associated with early onset of type 2 diabetes whereas

217 type 2 diabetes patients assigned to MGND topic are associated with late onset of type 2

- 218 diabetes.
- 219

220 We performed seven secondary analyses to validate the inferred comorbidity topics. First, we fit

ATM models with different model structures using 80% training data, and computed their

- prediction odds ratios using 20% testing data. The ATM model structure with 10 topics and age-
- dependent topic loadings modelled as a spline function performed optimally (Supplementary
- Figure 7; see Methods). Second, we confirmed that ATM attained higher prediction odds ratios
- than LDA across different values of the number of topics (Supplementary Figure 8). Third, we

It is made available under a CC-BY 4.0 International license .

- reached similar conclusions using evidence lower bounds³⁹ (ELBO; see Supplementary Table 1)
- when fitting the model without splitting training and testing data (Supplementary Figure 9).
- 228 Fourth, we confirmed that collapsed variational inference ⁴⁰ outperformed mean-field variational
- inference ³⁷ (Supplementary Figure 10). Fifth, we computed a co-occurrence odds ratio
- evaluating whether diseases grouped into the same topic by ATM in the training data have higher
- than random probability of co-occurring in the testing data (Supplementary Table 1). The co-
- 232 occurrence odds ratio is consistently above one and increases with the number of comorbid
- diseases, for each inferred topic (Supplementary Figure 11). Sixth, we compared the topic
- loadings by repeating the inference on female-only or male-only populations and observed no
- 235 major discrepancies, except for genitourinary topics MGND and FGND (topic loading R^2
- (female vs. all) = 0.788, topic loading R^2 (male vs. all) = 0.773, Supplementary Figure 12).
- 237 Lastly, we verified that BMI, sex, Townsend deprivation index, and birth year explained very
- 238 little of the information in the inferred topics (Supplementary Table 3).
- 239

240 Disease topics capture known biology as well as the age-dependency of comorbidities for the

same diseases. For example, early onset of essential hypertension is associated with the CVD

topic ⁴³, which captures the established connection between lipid dysfunction

243 ("hypercholesterolemia") and cardiovascular diseases⁴⁴, while later onset of essential

244 hypertension is associated with the CER topic, which pertains to type 2 diabetes, obesity and

- 245 COPD (Figure 4A). Continuously varying age-dependent topic loadings for all 10 topics,
- restricted to diseases with high topic loadings, are reported in Supplementary Figure 13 and

247 Supplementary Table 5. We note that most diseases have their topic loadings concentrated into a

- single topic (Figure 4B, Supplementary Figure 14A and Supplementary Table 4), and that most
 individuals have their topic weights concentrated into 1-2 topics (Figure 4C and Supplementary
- 250 Figure 14B). For diseases spanning multiple topics (Supplementary Figure 6 and Supplementary
- Table 4), the assignment of type 2 diabetes patients to the CVD topic is consistent with known
- pathophysiology and epidemiology ^{45,46} and has been shown in other comorbidity clustering
 studies, e.g. with the Beta Cell and Lipodystrophy subtypes described in ref. ³⁵ and the severe
- studies, e.g. with the Beta Cell and Lipodystrophy subtypes described in ref. ³⁵ and the severe
 insulin-deficient diabetes (SIDD) subtype described in ref.¹⁴, which are characterised by early
- 255 onset of type 2 diabetes and have multiple morbidities including hypercholesterolemia,
- 256 hyperlipidemia, and cardiovascular diseases ⁴⁷. In addition, early-onset breast cancer and late-
- 257 onset breast cancer are associated with different topics, e.g. NRI and FGND, consistent with
- 258 known treatment effects for breast cancer patients which increase susceptibility to infections,
- especially bacterial pneumonias⁴⁸ and hypothyroidism ⁴⁹
- 260

We conclude that ATM identifies latent disease topics that robustly compress age-dependent comorbidity profiles and capture disease comorbidities both within and across Phecode systems.

- 263
- 264

It is made available under a CC-BY 4.0 International license .

265 Disease subtypes defined by distinct topics are genetically heterogeneous

266 We sought to define disease subtypes based on the diagnosis-specific topic probabilities of each

- 267 disease diagnosis. We assigned a discrete topic assignment to each disease diagnosis based on its
- 268 maximum diagnosis-specific topic probability, and defined the disease subtype of each disease
- 269 diagnosis based on the topic assignment. We restricted our disease subtype analyses to 52
- diseases with at least 500 diagnoses assigned to each of two distinct subtypes (Methods,
- 271 Supplementary Figure 6, Supplementary Figure 15, and Supplementary Table 6).
- 272

273 Age-dependent distributions of subtypes (topics) for four diseases (type 2 diabetes, asthma,

- 274 hypercholesterolemia, and essential hypertension) are reported in Figure 5A and Supplementary
- Table 7; results for all 52 diseases are reported in Supplementary Figure 16 and Supplementary
- Table 7. The number of subtypes can be large, e.g. six subtypes for essential hypertension.
- 277 Subtypes are often age-dependent, e.g. for the CVD and MGND subtypes of type 2 diabetes^{14,35}
- 278 (discussed above).
- 279

280 ATM and the resulting subtype assignments do not make use of genetic data. However, we used 281 genetic data to assess genetic heterogeneity across inferred subtypes of each disease. We first 282 assessed whether polygenic risk scores (PRS) for overall disease risk varied across subtypes of each disease; PRS were computed using BOLT-LMM with five-fold cross validation ^{50,51} (see 283 284 Methods and Code Availability). Results for four diseases (from Figure 5A) are reported in 285 Figure 5B and Supplementary Table 8; results for all 10 well-powered diseases (10 of 52 286 diseases with highest z-scores for nonzero SNP-heritability) are reported in Supplementary Figure 17 and Supplementary Table 8. We identified 18 disease-topic pairs (of 100 disease-topic 287 288 pairs analysed) for which PRS values in disease cases vary with patient topic weight. For 289 example, for essential hypertension, hypercholesterolemia, and type 2 diabetes, patients assigned 290 to the CVD subtype had significantly higher PRS values than patients assigned to other subtypes. 291 For essential hypertension, patients assigned to the CER subtype had significantly higher PRS 292 values: for type 2 diabetes, patients assigned to the CER subtype had lower PRS values than the 293 CVD subtype, even though the majority of type 2 diabetes diagnoses are assigned to the CER 294 subtype. We further verified that most of the variation in PRS values with disease subtype could not be explained by age⁵² or differences in subtype sample size (Supplementary Figure 18). 295 296 These associations between subtypes (defined using comorbidity data) and PRS (defined using 297 genetic data) imply that disease subtypes identified through comorbidity are genetically 298 heterogeneous, consistent with differences in disease aetiology.

299

300 We further investigated whether subtype assignments (defined using comorbidity data) revealed

301 subtype-specific excess genetic correlations. We estimated excess genetic correlations between

- 302 pairs of disease subtypes (relative to genetic correlations between the underlying diseases).
- 303 Excess genetic correlations for 15 disease subtypes (spanning 11 diseases and 3 topics: CER,
- MGND and CVD) are reported in Figure 6A and Supplementary Table 9 (relative to genetic
 correlations between the underlying diseases; Figure 6B), and excess genetic correlations for all

It is made available under a CC-BY 4.0 International license .

306 89 well-powered disease subtypes (89 of 378 disease subtypes with z-score > 4 for nonzero SNP-

- 307 heritability) are reported in Supplementary Figure 19 and Supplementary Table 9. Genetic
- 308 correlations between pairs of subtypes involving the same disease were significantly less than 1
- 309 (FDR<0.1) for hypertension (CER vs. CVD: $\rho = 0.86 \pm 0.04$, P=0.0004; MGND vs. CVD: $\rho =$
- 310 0.74 ± 0.05, P=3× 10⁻⁸) and type 2 diabetes (CER vs. MGND: $\rho = 0.64 \pm 0.09$, P=8 × 10⁻⁵)
- 311 (Figure 6A; Supplementary Table 9). In addition, we observed significant excess genetic
- correlations (FDR<0.1) for 8 pairs of disease subtypes involving different diseases (Figure 6A;
- 313 Supplementary Table 9). We verified that the excess genetic correlations could not be explained
- by non-disease-specific differences in the underlying topics (which are weakly heritable;
- Supplementary Table 3) by repeating the analysis using disease cases and controls with matched
- topic weights (Methods, Supplementary Figure 20). We also estimated subtype-specific SNP-
- heritability and identified some instances of differences between subtypes, albeit with limitedpower (Supp Table 10).
- 319

Finally, we used the population genetic parameter $F_{ST}^{53,54}$ to quantify genome-wide differences in allele frequency between two subtypes of the same disease; we used F_{ST} on control sets with matched topic weights to assess statistical significance while accounting for non-disease-specific

- 323 differences in the underlying topics (excess F_{ST} ; Methods). We determined that 63 of 104 pairs 324 of disease subtypes involving the same disease (spanning 29 of 49 diseases, excluding 3 diseases
- 325 that did not have enough controls with matched topic weights) had significant excess F_{ST}
- estimates (FDR < 0.1) (Supplementary Figure 21, Supplementary Table 11). For example, the
- 327 CVD, CER, and MGND subtypes of type 2 diabetes had significant excess F_{ST} estimates (F-

statistic=0.0003, P=0.001 based on 1,000 matched control sets). This provides further evidence that disease subtypes as determined by comorbidity have different molecular and physiological aetiologies.

331

333

- 332 We conclude that disease subtypes defined by distinct topics are genetically heterogeneous.
- 334 Disease-associated SNPs have subtype-dependent effects

335 We hypothesised that disease genes and pathways might differentially impact the disease

336 subtypes identified by ATM. We investigated the genetic heterogeneity between disease

337 subtypes at the level of individual disease-associated variants. We employed a statistical test that

tests for SNP x topic interaction effects on disease phenotype in the presence of separate SNP

and topic effects (Methods). We verified via simulations that this statistical test is well-calibrated

- 340 under a broad range of scenarios with no true interaction, including direct effect of topic on
- 341 disease, direct effect of disease on topic, pleiotropic SNP effects on disease and topic, and
- nonlinear effects (Supplementary Figure 22). We also assessed the power to detect true
- 343 interactions (Supplementary Figure 23). To limit the number of hypotheses tested, we applied
- 344 this test to independent SNPs with genome-wide significant main effects on disease (Methods).
- We thus performed 2,530 statistical tests spanning 888 disease-associated SNPs, 14 diseases, and
- 346 35 disease subtypes (Supplementary Table 12). We assessed statistical significance using global

It is made available under a CC-BY 4.0 International license .

FDR<0.1 across the 2,530 statistical tests. We also computed main SNP effects specific to each
quartile of topic weights across individuals, as an alternative way to represent SNP x topic
interactions.

350

351 We identified 43 SNP x topic interactions at FDR<0.1 (Figure 7, Supplementary Figure 24, 352 Supplementary Table 13 and Supplementary Table 14). Here, we highlight a series of examples. 353 First, the type 2 diabetes-associated SNP rs1063192 in the CDKN2B locus has a higher odds 354 ratio in the top quartile of CVD topic weight (1.19 ± 0.02) than in the bottom quartile (1.08 ± 0.02) 355 (P=4 \times 10⁻⁴ for difference). *CDKN2B* is associated with both coronary artery disease and type 2 diabetes^{55–59}, suggesting that shared pathways underlie the observed SNP x topic interaction. 356 357 Second, the asthma-associated SNP rs1837253 in the TSLP locus has a higher odds ratio in the 358 top quartile of SRD topic weight (1.17 ± 0.02) than in the bottom quartile (1.05 ± 0.02) (P=1 \times 10⁻⁴ for difference). *TSLP* plays an important role in promoting Th2 cellular responses 359 360 and is considered a potential therapeutic target, which is consistent with assignment of asthma and atopic/contact dermatitis⁶⁰ to the SRD topic (Supplementary Table 4). Third, the 361 hypertension-associated SNP rs3735533 within the HOTTIP long non-coding RNA has a lower 362 363 odds ratio in the top quartile of CVD topic weight (1.07 ± 0.02) than in the bottom quartile (1.13 ± 0.02) . HOTTIP is associated with blood pressure^{27,61} and conotruncal heart 364 365 malformations⁶². Fourth, the hypothyroidism-associated SNP rs9404989 in the HCG26 long noncoding RNA has a higher odds ratio in the top quartile of FGND topic weight (1.90±0.24) than in 366 the bottom quartile (1.19 \pm 0.13) (P=3 × 10⁻³ for difference). Hypothyroidism associations have 367 368 been reported in the HLA region²⁷, but not to our knowledge in relation to the HCG26. To verify 369 correct calibration, we performed control SNP x topic interaction tests using the same 888 370 disease-associated SNPs together with random topics that did not correspond to disease subtypes, 371 and confirmed that these control tests were well-calibrated (Supplementary Figure 24B). 372 373 We conclude that genetic heterogeneity between disease subtypes can be detected at the level of 374 individual disease-associated variants. 375

It is made available under a CC-BY 4.0 International license .

377 Discussion

- 378 We have introduced an age-dependent topic modelling (ATM) method to provide a low-rank 379 representation of longitudinal disease records, leveraging age-dependent comorbidity profiles to identify and validate biological subtypes of disease. Our study builds on previous studies on 380 topic modelling^{37,38,40,63}, genetic subtype identification^{13–15}, and low-rank modelling of multiple 381 diseases to identify shared genetic components^{25–27}. We highlight three specific contributions of 382 our study. First, we incorporated age at diagnosis information into our low-rank representation, 383 complementing the use of age information in other contexts^{32,52,64}; we showed that age 384 385 information is highly informative for our inferred comorbidity profiles in both simulated and 386 empirical data, emphasising the importance of accounting for age in efforts to classify disease diagnoses. Second, we identified 52 diseases with heterogeneous comorbidity profiles that we 387 used to define disease subtypes, many of which had not previously been identified 388
- 389 (Supplementary Table 15). Third, we used genetic data (including PRS, genetic correlation and
- F_{ST} analyses) to validate these disease subtypes, confirming that the inferred subtypes reflect true
- 391 differences in disease aetiology.
- 392

We emphasise three downstream implications of our findings. First, it is of interest to performdisease subtype-specific GWAS on the disease subtypes that we have identified here, analogous

disease subtype-specific GWAS on the disease subtypes that we have identified here, analogous
 to GWAS of previously identified disease subtypes¹³⁻¹⁵. Second, our findings motivate efforts to

- 396 understand the functional biology underlying the disease subtypes that we identified; the recent
- availability of functional data that is linked to EHR is likely to aid this endeavor^{29,65}. Third, it is of interest to apply ATM to identify age-dependent comorbidity profiles and disease subtypes in
- other EHR data sets^{30,31}; establishing representations of disease topics that are transferable and
 robust across different healthcare systems and data sources represents a major future challenge.
- 401

402 Our findings reflect a growing understanding of the importance of context, such as age, sex,

- 403 socioeconomic status and previous medical history, in genetic risk ^{52,66,67}. To maximise power
- 404 and ensure accurate calibration, context information needs to be integrated into clinical risk
- 405 prediction tools that combine genetic information (such as polygenic risk scores ^{1,68}) and non-
- 406 genetic risk factors. Our work focuses on age, but motivates further investigation of other
- 407 contexts. We note that aspects of context are themselves influenced by genetic risk factors, hence
- 408 there is an open and important challenge in determining how best to combine medical history
- 409 and/or causal biomarker measurements with genetic risk to predict future events 69 .
- 410
- 411 We note several limitations of our work. First, age at diagnosis information in EHR data may be
- an imperfect proxy for true age at onset, particularly for less severe diseases that may be detected
- 413 as secondary diagnoses; although perfectly accurate age at onset information would be ideal, our
- 414 study shows that that imperfect age at diagnosis information is sufficient to draw meaningful
- 415 conclusions. Second, raw EHR data may be inaccurate and/or difficult to parse¹; again, although
- 416 perfectly accurate EHR data would be ideal, our study shows that imperfect EHR data is

It is made available under a CC-BY 4.0 International license .

- 417 sufficient to draw meaningful conclusions. Third, our ATM approach incurs substantial
- 418 computational cost (Supplementary Table 16); however, analyses of biobank-scale data sets are
- 419 computationally tractable, with our main analysis requiring only 4.7 hours of running time.
- 420 Finally, we have applied ATM to a UK population of predominantly European ancestry; it is of
- 421 interest to apply ATM to diverse populations^{30,31}. Despite these limitations, ATM is a powerful
- 422 approach for identifying age-dependent comorbidity profiles and disease subtypes.
- 423

424 Acknowledgements

- 425
- This research has been conducted using the UK Biobank Resource; application number 12788.
- 428 Funded by Wellcome (BST00080- H503.01 to XJ, 100956/Z/13/Z to GM, https://
- 429 wellcome.org); the Li Ka Shing Foundation (to GM, https://www.lksf.org); NIH grants R01
- 430 HG006399, R01 MH101244, and R37 MH107649 (to ALP); The Alan Turing Institute
- 431 (https://www.turing.ac.uk), Health Data Research UK (https://www.hdruk.ac.uk), the Medical
- 432 Research Council UK (https://mrc.ukri.org), the Engineering and Physical Sciences Research
- 433 Council (EPSRChttps://epsrc.ukri.org) through the Bayes4Health programme Grant
- 434 EP/R018561/1, and AI for Science and Government UK Research and Innovation (UKRI,
- 435 https://www.turing.ac.uk/ research/asg) (to CH); BHF Chair award CH/12/2/29428 (to XJ). This
- 436 work was supported by core funding from the: British Heart Foundation (RG/13/13/30194;
- 437 RG/18/13/33946), BHF Cambridge Centre of Research Excellence (RE/13/6/30180) and NIHR
- 438 Cambridge Biomedical Research Centre (BRC-1215-20014). The funders had no role in study
- 439 design, data collection and analysis, decision to publish, or preparation of the manuscript.
- 440
- 441 This work uses data provided by patients and collected by the NHS as part of their care and
- 442 Support. Computation used the Oxford Biomedical Research Computing (BMRC) facility, a
- 443 joint development between the Wellcome Centre for Human Genetics and the Big Data Institute
- 444 supported by Health Data Research UK and the NIHR Oxford Biomedical Research Centre. The
- views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the
- 446 Department of Health. We thank Kushal Dey, Luke Kelly and Yunlong Jiao for the discussion.
- 447

448 Data availability

- 449 UK Biobank data is publicly available at <u>https://www.ukbiobank.ac.uk/</u>.
- 450

451 Code availability

- 452 Open-source software implementing the ATM method is available at <u>https://github.com/Xilin-</u>
- 453 Jiang/ATM. BOLT-LMM is available at <u>https://alkesgroup.broadinstitute.org/BOLT-LMM/</u>.
- 454 Heritability and genetic correlation analysis were performed using LDSC, which is available at

It is made available under a CC-BY 4.0 International license .

- 455 <u>https://github.com/bulik/ldsc</u>. PLINK v1.9, which was used for F_{ST} and association tests, is
- 456 available at <u>https://www.cog-genomics.org/plink/</u>.

457

It is made available under a CC-BY 4.0 International license .

459 Methods

460 Age-dependent topic model (ATM)

461 Our Age-dependent topic model (ATM) is a Bayesian hierarchical model to infer latent risk

462 profiles for common diseases. The model assumes that each individual possesses several age-

463 evolving disease profiles (topic loadings), which summarise the risk over age for multiple

diseases that tend to co-occur within an individual's lifetime, namely the age specific multi-

465 morbidity profiles. At each disease diagnosis, one of the disease profiles is first chosen based on

466 individual weights of profile composition (topic weights), the disease is then sampled from this

- 467 profile conditional on the age of the incidence.
- 468

469 We constructed a Bayesian hierarchical model to infer *K* latent risk profiles for *D* distinct

470 common diseases. Each latent risk profile (comorbidity topics) is age-evolving and contains risk

- trajectories for all *D* diseases considered. Each individual might have a different number of
- 472 diseases, while the disease risk is determined by the weighted combination of latent risk topics.
- 473 The indices in this note are as follows:

474 • s = 1, ..., M;

475 • $n = 1, ..., N_s;$

- 476 i = 1, ..., K;
- 477 j = 1, ..., D;

478 where *M* is the number of subjects, N_s is the number of records within s^{th} subject, *K* is the 479 number of topics, and *D* is the total number of diseases we are interested in. The plate notation of 480 the generative model is summarised in Supplementary Figure 1:

- 481 $\theta \in \mathbb{R}^{M \times K}$ is the topic weight for all individuals (referred to as patient topic weights), 482 each row of which ($\in \mathbb{R}^{K}$) is assumed to be sampled from a Dirichlet distribution with 483 parameter α . α is set as a hyper parameter: $\theta_{s} \sim Dir(\alpha)$.
- 484 $z \in \{1, 2, ..., K\}^{\sum_{S} N_{S}}$ (referred to as diagnosis-specific topic probability) is the topic 485 assignment for each diagnosis $w \in \{1, 2, ..., D\}^{\sum_{S} N_{S}}$. Note the total number of 486 diagnoses across all patients are $\sum_{S} N_{S}$. The topic assignment for each diagnosis is 487 generated from a categorical distribution with parameters equal to s^{th} individual topic 488 weight: $z_{sn} \sim Multi(\theta_{s})$.

489 •
$$\beta(t) \in F(t)^{K \times D}$$
 is the topic loading which is $K \times D$ functions of age t. $F(t)$ is the
490 class of functions of t. At each plausible t, the following is satisfied: $\sum_{i} \beta_{ii}(t) = 1$. In

491 practice we use softmax function to ensure above is true and add smoothness by constrain $arn(n,T,\Phi(t))$

492
$$F(t)$$
 to be spline or polynomial functions: $\beta_{ij}(t) = \frac{exp(p_{ij}^T \phi(t))}{\{\sum_{j=1}^{D} exp(p_{ij}^T \phi(t))\}}$, where

493 $p_{ij} = \{ p_{ijd} \}; d = 1, 2, ..., P; P$ is the degree of freedom that controls the smoothness;

494 $\phi(t)$ is polynomial and spline basis for age t.

It is made available under a CC-BY 4.0 International license .

495	•	$w \in \{1, 2,, D\}^{\sum_{s} N_s}$ are observed diagnoses. The n^{th} diagnosis of s^{th} individual w_{sn}
496		is sampled from the topic $\beta_{z_{sn}}(t)$ chosen by z_{sn} : $w_{sn} \sim Multi(\beta_{z_{sn}}(t_{sn}))$, here t_{sn} is the
497		age of the observed age at diagnosis of the observed diagnosis w_{sn} .

498

499 The values of interest in this model are global topic parameter β , individual (patient) level topic 500 weight θ , and diagnosis-specific topic probability *z*. Based on the generative process above, we

501 notice that each patient is independent conditional on α . Therefore, the inference of θ and

- 502 z(discussed below) could be performed by looping each individual in turn.
- 503

507

504 The key element in our model is age-evolving risk profiles, which is achieved by model the 505 comorbidity trajectories $\beta(t) \in F(t)^{K \times D}$ as functions of age. The functionals F(t) considered 506 are linear, quadratic, cubic polynomials, and cubic splines with one, two and three knots.

508 Inference of ATM

509 The variables of interest are global topic parameter $\beta(t)$, individual (patient) level topic weight

510 θ , and diagnosis-specific topic probability z of each diagnosis. We could adopt an EM strategy,

511 where in the E-step we first estimate posterior distribution of θ and z, then in the M-step we

512 estimate β which maximises the evidence lower bound (ELBO).

513

514 The details of the inference is explained in Supplementary Note. In summary, in a Bayesian

- setting, the model could be evaluated by the evidence function $p(w|\alpha,\beta)$. The best $\beta(t)$ is found
- 516 by maximise the evidence function, while for θ and z we aim to find or approximate their
- 517 posterior distribution $p(z, \theta | w, \alpha, \beta)$. Given that the posterior distribution is intractable, we use 518 variational distribution $q(z, \theta)$ to approximate them. Now we could write the evidence function 519 as:
- 520

$$p(w|\alpha,\beta) = L(z,\theta,\beta,\alpha) + KL(q||p),$$

521 here $KL(q||p) = -\int_{z,\theta} q(z,\theta) \ln \frac{p(z,\theta | w,\alpha,\beta)}{q(z,\theta)}$ is the KL divergence. Since KL divergence is

522 always positive, $L(z, \theta, \beta, \alpha)$ is a lower bound of the evidence function:

523
$$L(z,\theta,\beta,\alpha) = E_q\{ \ln p(w,z,\theta \mid \alpha,\beta) - \ln q(z,\theta) \}.$$

524

525 When finding the posterior of θ and z, we want $\ln q(z, \theta)$ to be as close to the posterior $p(z, \theta \mid w, \alpha, \beta)$ as possible. Since $KL(q \mid p) = 0$ when $q(z, \theta) = p(z, \theta \mid w, \alpha, \beta)$, this could 526 527 be achieved by minimising KL(q||p) or maximise $L(z, \theta, \beta, \alpha)$. The most commonly used form of $q(z, \theta)$ assume the distribution is factorised, which might cause instability when signal-to-528 noise ratio is low⁷⁰. Therefore, more accurate inference methods such as collapsed variational 529 inference is considered⁴⁰. Comparison of the evidence lower bound $L(z, \theta, \beta, \alpha)$ shows collapsed 530 531 variational inference is consistently more accurate than LDA (Supplementary Figure 8). Therefore we choose the collapsed variational inference⁴⁰. The collapsed variational inference is 532 533 achieved by integrate out θ from the likelihood function $p(w, z, \theta \mid \alpha, \beta)$ and find the

It is made available under a CC-BY 4.0 International license .

- approximated posterior distribution q(z). For detailed derivation, the comparison between
- collapsed variational inference and mean-field variational inference, and update algorithms, seeSupplementary Note.
- 537
- 538 When finding the $\beta(t)$ that maximises the evidence function, we again maximise $L(z, \theta, \beta, \alpha)$.
- 539 Maximising $L(z, \theta, \beta, \alpha)$ with respect to $\beta(t)$ does not have an analytical solution due to its
- 540 softmax structure. We use local variational methods and numeric optimisation to find the 541 distribution of $\beta(t)$. Details are provided in Supplementary Note.
- 542
- 543 We extract topic weights at patient-level and diagnosis-level from the posterior distribution 544 inferred from the data. Our model has the desired property that each patient and patient-diagnosis 545 are assigned to comorbidity topics. The model estimates the posterior distribution q(z), which is 546 a categorical distribution (Supplementary Note.) Several metrics related to topic assignments 547 could be derived from the q(z):
- Each patient-diagnosis (incident disease) has a diagnosis-specific topic probability, which is computed as $E_q\{z_n\}$.
- Each patient has a posterior topic assignment θ_s , which is a dirichlet distribution $\theta_s \sim$ 551 $Dir(\alpha + \sum_{n=1}^{N_s} E_q\{z_n\})$. The topic weights of each patient is the mode of this
- 552 Dirichlet distribution $\frac{\sum_{n=1}^{N_S} E_q\{z_n\}}{\sum_{i=1}^{K} \sum_{n=1}^{N_S} E_q\{z_{ni}\}}$ (we used $\alpha = 1$). The value is used as the patient bow-rank representation of disease history, for analysis including PRS association with
- 554 comorbidity within cases and G x Topic interaction analysis.
- The average topic assignments of disease *j* is the mean over all incidences $\overline{E_q\{z_{sn \in \{w_{sn}=j\}}\}}$. This metric is used to measure which comorbidity topic a disease is associated with (Figure 4B), and it is equivalent to a weighted average of topic loadings (for the specific weighted average expression, see equation 5 of Supplementary Note). A disease assigned to multiple topics is considered to have comorbidity subtypes.
- A hard assignment of a patient-diagnosis to a subtype is based on the max value of the vector $E_q\{z_n\}$. The incident disease is assigned to topic $argmax_i$ ($E_q\{z_{ni}\}$).
- 562

563 Metrics for evaluating ATM

ATM is evaluated for different purposes, which requires different metrics (Supplementary Table
1). Here we list the details of the four metrics considered: *Prediction odds ratio, Evidence Lower Bound (ELBO), AURPC, and Co-occurrence odds ratio.*

- 567
- 568 *Prediction odds ratio:* To compare models of different topic numbers and configuration of age
- 569 profiles, we compare the prediction odds ratio of each model. Briefly, prediction odds ratio is
- 570 defined on 20% held-out test data as the odds that the true diseases are within the top 1%
- 571 diseases predicted by ATM (trained on 80% of the training set and uses earlier diagnoses as

It is made available under a CC-BY 4.0 International license .

input), divided by the odds that the true diseases are within the top 1% of diseases ranked byprevalence.

574

575 Specifically, we separate UK Biobank patients into a training set (80%) and a testing set (20%). 576 On the training set, we estimate the comorbidity topic loadings. On the testing set, we fix the 577 topic loadings and infer the patient topic weights to predict the next disease in chronological 578 order. The topic loadings are estimated using the *n* diseases and compute the risk rank of 579 diseases at the age of the n+1 disease. The odds ratio is computed by the odds of the n+1 disease 580 being in the top 1% of diseases versus being in the top 1% most prevalent diseases. We use the 581 top 1% most prevalent diseases instead of randomly chosen diseases as it represents a naive 582 prediction model that predicts disease based on prevalence. The patient topic weights 583 computation is in section Inference of ATM and the risk is computed as the linear combination 584 of topics using topic weights as coefficients. We also compute the prediction odds ratio using the 585 LDA model. We repeat the procedure for 10 times for each model configuration. 586 587 We compared the prediction odds ratio for topic number between 5 to 20, with linear, quadratic 588 polynomial, cubic polynomial, and splines with one, two and three knots. We also compare the 589 ATM model with the LDA model of topic number between 5 to 20.

590

Evidence Lower Bound (ELBO): ELBO evaluated the accuracy of the variational inference
method on a specific data set. Mathematical expression of ELBO for ATM is presented in
equation 9 in Supplementary Note. To find the best model that fit to the entire dataset, we
evaluate the ELBO for models with topic numbers between 5 to 20, 25, 30, and 50 topics and age
profiles configured by linear, quadratic polynomial, cubic polynomial, and splines with one, two
and three knots. Each model is run for 10 times with random initialisations. We choose the
model that has the highest ELBO after converging.

598

599 AURPC: To evaluate whether a model could capture the comorbidity subtypes in simulation 600 analysis, we compute the precision, recall, and area under precision-recall curve (AUPRC) to 601 correctly classify disease diagnosis to be from the topic that it is generated from. The topic of 602 each diagnosis is determined by diagnosis-specific topic probability. Note we could only 603 evaluate AUPRC in simulations where the truth is known.

604

605 *Co-occurrence odds ratio:* To verify that the comorbidity profiles that the model captured are 606 capturing diseases that are more likely to present within the same individual, we estimate the 607 odds ratio of the disease duo, trio, quartet, and quintet that are captured by the topic versus that 608 of random combinations. We divide the population into an 80% training set and a 20% testing

- set. We trained the ATM model with five random initialisations and kept the inference with the
- 610 highest ELBO. Each disease is assigned to a topic by the highest average topic assignments.
- 611 (section Inference of ATM) We focus on the top 100 diseases ranked by prevalence to avoid the

It is made available under a CC-BY 4.0 International license .

- 612 combination being too rare to appear in the population. In the testing set, we computed the odds
- of individuals who have all diseases in the comorbidities versus the odds implied if all diseases
- are independent (computed as the product of disease prevalence). The odds ratio is computed for
- all combinations of duo, trio, quartet, and quintet that are assigned to the same topics. We
- 616 perform the same analysis using PCA for comparison.
- 617
- 618

619 Simulations of ATM method.

To test whether the algorithm could assign disease diagnosis to correct comorbidity profiles, we
simulated disease from two disease topics within a population of 10,000, using following
parameters:

- 623 M = 10,000;
- 624 $\overline{N_S} = 6.1;$
- 625 $N_S \sim exp\{\overline{N_S}\};$
- 626 D = 20;
- 627 K = 2;

Here *M* is the number of individuals in the population, $\overline{N_s}$ is the average number of diseases for 628 629 each individual, D is the total number of diseases, K is the number of comorbidity topics. The 630 distribution of disease number per-individual $N_{\rm s}$ is sampled from an exponential distribution, which matches those from UK Biobank data (Supplementary Figure 26). According to equation 631 3.1 in Ghorbani et al.⁷⁰, whether the topic model could capture the true latent structure is 632 determined by the information signal-to-noise ratio and could be evaluated with limits $M \rightarrow$ 633 ∞ ; $D \to \infty$; $\frac{D}{M} \to \delta$, where δ is a constant. Therefore we choose D and M at scales that make $\frac{D}{M}$ 634 635 approximately similar to those of the UK Biobank dataset (Samples size = 282,957; distinct 636 disease number = 349).

637

638 The simulated topics loadings are constructed as follows:

- All but *K* diseases are simulated to be associated with comorbidity profiles. Each of them has a risk period of 30 years and overlaps for 10 years with the next disease. For
 example, if disease 1 has a risk period from 30 to 59 years of age, disease 2 will have a risk period between 50 to 79 years of age. When the risk period reaches the maximal age, the truncated part will be carried to the next disease to create diseases with shorter risk period. All risk periods are assigned a value 1.
- 645 *K* diseases that are not associated with comorbidity are simulated to span all topics. The 646 values of these diseases are sampled from $Unif(0, \frac{0.1}{K})$ for each topic. Here *K* is the 647 number of topics.
- The age profiles are then normalised at each age point to ensure $\sum_{j=1}^{D} \beta_j(t) = 1$ for all t. With this constraint we could sample a disease at each age t using a multinomial probability with the topic loading as the parameter. The age range of the simulated topics

It is made available under a CC-BY 4.0 International license .

is 30 to 81 years of age, which is the minimal and maximal age at diagnosis of incident
disease in the UK Biobank population. An example of a simulated topic is shown in
Supplementary Figure 27.

654

For each individual, we sampled the Dirichlet parameter α from a gamma distribution (shape = 50, rate = 50). Topic loadings are sampled from the Dirichlet distribution for each patient as the generative process. For each patient, we first sample the number of diseases N_S . For each incident disease, we sample the disease age from uniform distribution between age 30 to 81 and a topic from the topic loading. We then choose the incident disease based on the age at diagnosis from the chosen topic. The procedure follows the generative process described in Supplementary Note.

662

663 Since in real data we only use the first age at diagnosis for diseases that are recorded repeatedly 664 within the same patient, we filter the simulated diseases accordingly. The filtered data are fed

665 into the inference functions to infer the latent topics and disease assignments. The inferred topics

resemble the true topics used to simulate diseases as shown in Supplementary Figure 27. For the

667 initialisation of each inference, we first sample β and θ from the Dirichlet distribution of non-

668 informative hyperparameters, then initialise other variables parameters following the generative 669 process. The variational inference converged where the relative increase of ELBO is below 10^{-6} . 670

To simulate disease having distinct comorbidity subtypes, we first simulate diseases using the procedure described above. We consider two scenarios: (1) the subtype of diseases have the same age at diagnosis distribution. (2) the subtypes of disease have distinct age at diagnosis distribution.

675

We create diseases with distinct comorbidity profiles by combining diseases that are sampled from distinct topics and labelling them as a single disease. We first chose one disease (**disease**

A) then sampled a proportion of a second disease (disease B) to label as disease A. The

679 proportion is varied to create a different sample size ratio of the two subtypes. In scenario one,

680 **disease B** is a disease that has the exact same age distribution as **disease A** but from the other

681 topic. In scenario two, disease B is from the other topic and has a different age distribution (age

at diagnosis moves up for 20 years, 10 years, or 5 years, respectively) than **disease A**. After

683 changing the labels of **disease B** to be the same as **disease A**, we used the inference procedure

- 684 described as above to get the posterior distribution.
- 685

To evaluate whether a model could capture the comorbidity subtypes, we compute the precision,

recall, and area under precision-recall curve (AUPRC) to correctly classify incident **disease B** to

- be from the topic that it is generated from. The topic of each diagnosis is determined by
- 689 diagnosis-specific topic probability. We use other diseases from the topic of **disease B** to
- benchmark the topic label. Topic modelling on the simulated data is performed with both ATM

It is made available under a CC-BY 4.0 International license .

and LDA (both implemented using collapsed variational inference for fair comparison) tocompare the performances.

693

694 We evaluate the subtype classification with varying values for three simulation parameters:

- ratio of sample sizes between the two subtypes. We change the ratio of the two subtypes
 by a grid between 0 to 0.9 with a step size 0.1. The default value of sample size ratio is
 set as 0.1 in other simulations to test for other parameters that have impacts on the
 precision and recall.
- Simulated population size. We simulated population sizes equal to 200, 500, 1000, 2000,
 5000, and 10,000. The default population size is 10,000 in other simulations.
- Number of distinct diseases. We simulated datasets with 20, 30, 40, and 50 distinct diseases, with 2, 3, 4 and 5 underlying disease topics respectively. The default number of distinct diseases is 20 in other simulations.
- Difference of age distribution. We considered three scenarios of subtype age distribution,
 with 0, 10, and 20 years of difference in the average age at diagnosis.
- 706
- 707

708 UK Biobank comorbidity data.

709 We analysed comorbidity data from 282,957 UK Biobank samples with diagnoses for at least 710 two of the 348 focal diseases that we studied (see below). We use the hospital episode statistics 711 (HES) data within the UK Biobank dataset, which records diseases using the ICD-10/ICD-10CM 712 coding system. Codes started with letters from A to N are kept as they correspond to disease 713 code (opposed to procedure codes). The disease records were mapped from ICD-10/ICD-10CM 714 codes to PheCodes using a three-step procedure: Firstly, we map the first four letters of each 715 ICD-10 records to the phecodes, using the map file downloaded from phewascatalog.org; 716 Secondly, we map the remaining records using ICD-10CM map file downloaded from 717 phewascatalog.org; Lastly, we map remaining records to a collapsed ICD-10CM mapping 718 system which only use the first four character of ICD-10CM codes. We also noticed an ICD-719 10/ICD-10CM code could map to multiple PheCodes. When a single ICD-10/ICD-10CM code s 720 mapped to more than one PheCodes, we only kept the Phecode that are mapped to the most ICD-721 10 codes (i.e. PheCode is constructed by combining ICD-10 that represent similar diseases. The 722 Phecode that represent a larger number of ICD-10 codes are more likely to be a well defined 723 disease, which we chose to keep.), which ensure that one ICD-10(CM) code only maps to one 724 PheCode. Using the procedure above, we mapped 99.7% ICD-10/ICD-10CM code to PheCodes, 725 with 4,637,127 records in total.

726

The mapped Phecodes are filtered to keep only the first age at diagnosis for the same diseases

within a patient. The age at diagnosis for each record is computed as the difference between

month of birth to the episode starting date. We then computed the occurrence of each disease in

the UK Biobank and kept 348 that have more than 1,000 occurrences (Supplementary Table 4).

It is made available under a CC-BY 4.0 International license .

731 Starting with all 488,377 UK Biobank patients (including both European and non-European

ancestries), we filtered the patients to keep only those who have at least two distinct diseases

- from the 348 focal diseases, as we are most interested in the comorbidity information. We treated
- the death as an additional disease (8,666 records) to evaluate if certain comorbidities are more
- 735 likely to lead to fatal events. After these procedures, there are in total 1,726,144 distinct records
- 736 across 282,957 patients.
- 737

To name the topics inferred from the UK Biobank, we take the sum of average topic assignments
(section Inference of ATM) over diseases that are within each phecode system and extract the
top 3 systems. Most of comorbidity topics are named using the first three topics (e.g. CER:
cardiovascular, endocrine/metabolic, respiratory), except for topics that are predominantly
associated with one system (LGI: lower gastrointestinal; UGI: upper gastrointestinal; CVD:

- 743 cardiovascular).
- 744

We present focal diseases for each topic in two ways. Firstly, we filter each topic using the profile mean value between age 30 to 81 to keep the top seven diseases. We chose seven for visualisation, as we found more diseases would be harder to read on a plot. Secondly, we also show seven diseases that have the highest average assignment to each topic. This will give a picture of diseases that are not the most prevalent in the population but are predominantly associated with the target topic.

751

752 To compare the comorbidity heterogeneity between age groups, we group the incidences for each 753 disease to two age groups: young group (<60 years of age) and old group (\geq 60 years of age). We 754 compute the average topic assignment of each group as described in section Inference of ATM. 755 Additionally, we inferred topics for male (984,554 records in 156,366 individuals) and female 756 (741,590 records in 126,591 individuals) populations respectively using a model with 10 topics 757 and spline function with one knot. We extract the average topic assignment for each disease, and 758 use Pearson's correlation to match the topics for both sexes to the topics inferred on the entire 759 population.

760

761 Each diagnosis could be assigned to a specific topic using max diagnosis-specific topic

- probability. We focus our disease heterogeneity analysis on 52 diseases that have at least 500incidences assigned to a secondary topic.
- 764

765 UK Biobank genotype data.

For all analyses except BOLT-LMM we use 488,377 UK Biobank participants. For BOLT-LMM

analyses, we constrain our analysis to 409,694 British Isle ancestry individuals to remove the

- possibility that topics are capturing population structure. For F_{ST} analysis with PLINK we used
- 769 805,426 genotyped SNPs; for BOLT-LMM PRS analysis we used 727,882 genotyped SNP with
- 770 MAF>0.1%; for genetic correlation analysis using LDSC, we used 157,756 Genotyped SNPs

It is made available under a CC-BY 4.0 International license .

mapped to HapMap3 SNPs; for BOLT-LMM and subsequent LDSC analysis that use imputed
SNPs, we used 1,201,838 imputed SNPs mapped to HapMap3 SNPs SNPs.

773

774 Polygenic risk scores (PRS) analysis.

To exclude the possibility of population stratification, we compute PRS using mixed-effect

association on the British Isle ancestry group (N = 409,694) for the 10 heritable diseases that

have the highest heritability z-scores. We used a mixed model to estimate effect size

implemented by BOLT-LMM and constructed genome-wide PRS ⁵⁰. For the computation of

PRS, we randomly sampled half of the British isle ancestry population (N = 204,847) for

computation efficiency (essential hypertension, arthropathy, asthma, and hypercholesterolemia)
 or sampled 9 controls for each case to ensure case proportion at or above 10% as recommended

by BOLT-LMM (type 2 diabetes, varicose veins of lower extremity, hypothyroidism, other

783 peripheral nerve disorders, major depressive disorder, and GRED). We used PLINK to select

genotyped SNPs with MAF > 0.1% as recommended in BOLT-LMM. For each disease, we used

785 5-fold cross validation to estimate effect sizes using BOLT-LMM and computed the PRS on the

held-out testing set. The predictive PRS are then used to compute the excess PRS over different

topic loadings, by a linear regression where PRS is the response variable and topic weights is thepredictor.

789

790 We compute the relative risk for each percentile of PRS using the following formula:

R

791

$$R_{pt,s} = \frac{n_{pt,s} \times 100}{n_s},$$

where $RR_{pt,s}$ is the relative risk of *s* subtype for the pt^{th} PRS percentile (computed for the entire population); $n_{pt,s}$ is the number of cases in *s* subtype that has PRS within the pt^{th} percentile; n_s is the number of cases in the *s* subtype.

795

796 Genetic correlation analysis.

For each disease and disease subtype, we use a case-control matching strategy to construct data to estimate coefficients for genetic correlation analysis. For each case in the disease group, we

to estimate coefficients for genetic correlation analysis. For each case in the disease group, we
pick four nearest neighbors (without replacement) from the control group, matching sex, BMI,

year of birth and 40 genetic principal components. The covariates are available within the UK

801 Biobank data set, over which we computed the principal components. We then compute the

Biobank data set, over which we computed the principal components. We then compute theEuclidean distance of the principal components to find the nearest neighbours in the population.

All cases are matched with four controls except for 401.1 essential hypertension which has a

- 804 sample size larger than 20% of the population. We match only one control for each hypertension 805 case.
- 806

807 We perform logistic regression with sex and top 10 principal components as covariates to

estimate the main variant effect of the 805,426 variants that are genotyped. We used PLINK 1.9

for association analysis⁷¹. With the summary statistics from the association analysis, we use

It is made available under a CC-BY 4.0 International license .

810 LDSC to map the summary statistics to HapMap3 SNPs and match the effect and non-effect

- alleles^{2,72}. Since UK Biobank is mostly of British Isle ancestry, we use the pre-computed LD
- score from the LDSC website. We estimated the heritability for each disease or disease subtype
- 813 which has more than 1000 incidences (378 diseases subtypes and diseases). We use 1000
- 814 incidence threshold as LDSC are more accurate with larger sample size. We focus on 71 disease
- and 18 disease subtypes that have heritability z-score above 4 for genetic correlation analysis.
- 816

817 The genetic correlation is computed for each pair of disease/subtypes using the same summary

- 818 statistics and LD score regression. We report the estimate of genetic correlation and z-scores.
- 819 Additionally, for pairs that involve subtypes (disease-subtype or subtype-subtype), we compute
- the excess genetic correlation, defined as the difference between the genetic correlation
- 821 involving subtypes and the genetic correlation involving all disease diagnoses. For example, the
- 822 genetic correlation between T2D-CER and hypertension-CVD is compared to the genetic
- 823 correlation between all T2D and all hypertension. The z-score and p-value of the genetic
- 824 correlation differences are reported. We note that genetic correlations between subtypes of the
- same disease are compared to 1. We only reported p-values of excess genetic correlation when
- both genetic correlation estimation has standard error <0.1 and at least one of the genetic
 correlation has |z-score|>4.
- 828

829 To avoid potential collider effects where subtypes are defined by topic components that are

- 830 independent of the diseases, we further match cases in each subtype with controls that match the
- topic loadings. We computed PCs from 23 variables (10 topic loadings, 10 PCs, year of birth,
- sex, and BMI) and use the nearest neighbour procedure (by Euclidean Distance) to find controls
- for each case. Here controls are chosen from individuals without the targeting disease, i.e. an
- 834 individual with one subtype of the target disease could not be a control for the other subtypes.
- 835 We performed the same analysis using this case-control matching procedure and compared the
- 836 genetic correlation with the case-control procedure described above. We perform the analysis for
- four diseases that have evidence for genetic subtypes: asthma, type 2 diabetes,
- 838 hypercholesterolemia, and hypertension. For one subtype (hypertension-CVD), the heritability
- 839 (0.0313, s.e. = 0.0289) is below threshold after matching the topic, which was excluded in
- 840 genetic correlation analysis.
- 841

842 $F_{\rm ST}$ analysis.

- 843 To evaluate the genetic heterogeneity between disease subtypes, we estimated the F_{ST} for 52
- 844 diseases that have at least 500 incidences assigned to a secondary topic. To test the statistical
- significance of Fst, we adopted a permutation strategy and sampled the same number of controls
- of similar topic weights distribution for each subtype. The topic weights are matched by
- 847 sampling (without replacement) the same number of controls for each dominant topic weight
- quartile of the cases (i.e. matching the topic that defines the subtype), which ensures the controls
- have the same topic weight stratification as the disease subtypes. We then compute the F_{ST} across

It is made available under a CC-BY 4.0 International license .

850	the control groups matched for subtypes. We excluded three diseases, "hypertension",
851	"hypercholesterolemia", and "arthropathy", from F_{ST} analysis as we do not have enough controls
852	that match topic weight distribution. The F_{STS} are computed using PLINK 1.9's weighted mean
853	across all genotyped SNPs, which report F statistics across all subtypes.
854	
855	We obtained 1,000 permutation samples and reported the permutation p-value. Under the
856	assumption that causal and non-causal variants have similar allele frequency differences across
857	the subtypes, F_{ST} could be a measure of causal genetic effect heterogeneity across subtypes.
858	
859	SNP x topic interaction test.
860	For the diseases that have heritability z-score above 4 in the UK Biobank, we further investigated
861	whether there are interactions between genetic risk factors with the topic loadings. We used a fit
862	a logistic regression model using following model:
863	$logit(p) = \beta_0 + \beta_1 * T + \beta_2 * T^2 + \beta_3 * G + \beta_4 * G * T$,
864	where T is individual topic weights for a specified topic, G is the genotype, and p is the
865	probability of getting the disease. We computed the test statistics under the null that $\beta_4 = 0$. We
866	used QQ plots to check that the test statistics are well calibrated for each disease-topic pair.
867	
868	Since the simulation shows the interaction test is underpowered when the variant effects are
869	small, we focus on the set of SNP that reaches genome-wide significance level to increase power
870	to detect interaction effects. We performed LD-clumping using $r^2 > 0.6$ to remove variants that
871	are in strong LD with the lead variants. We computed the test statistics using the model above
872	(for testing $\beta_{i} = 0$) and computed study-wise FDR across disease-topic pairs.
873	
874	To verify the significant interactions, we divided cases into quartiles based on topic loading for
875	each disease-topic pair, and randomly sampled two controls that match the topic loading for each
876	case. We estimated the main effect sizes for all GWAS-SNP within each quartile of topic
877	loadings to capture effects that are modulated by topic weights. We focus on the SNPs that have
878	significant interaction test statistics computed in the previous step and compare it with
879	background SNPs that have genome-wide significant main effects but no interaction effect
880	(P>0.05).
881	
882	Simulations of SNP x topic interaction
883	We simulate comorbidity with genetics to test interaction between genetic and comorbidity
884	topics. We simulated 100 independent variants with MAF randomly sampled from <i>Unif</i> (0, 0, 5).
885	We assumed an additive model and simulated genotypes for the population using Hardy-
886	Weinberg equilibrium. We simulated three types of genetic effects on topic and diseases on topic
887	of the simulation framework described in Simulations of ATM method section:
888	• Genetics-topic effect: each variant is simulated to have an linear effect of 0.04 on the
889	topic loading. We choose this value as after normalising the topic, a regression of causal

It is made available under a CC-BY 4.0 International license .

890	variant to topic would have an effect size approximately 0.01 which is similar to our						
891	observation in the UK Biobank. The number of variants that are causal to the topic varies						
892	between 2 to 20. We simulated the effect on one topic by adding additive SNP effects and						
893	normalise the topic loadings of each patient. The topic-disease causality is a natural						
894	consequence following the generative process of sampling data.						
895	• Genetic-disease-topic effect: we simulated a heritable disease that is causal to the topic.						
896	The disease is simulated with 20 causal variants each of effect size 0.15. We vary the						
897	disease-to-topic causal effect from 0.05 to 0.5, with a default value of 0.1 in other						
898	analyses (similar to the correlation we found in UK Biobank analysis). We simulated the						
899	effect on one topic by adding additive causal disease effects and normalise the topic						
900	loadings of each patient.						
901	• The genetic effect could interact with the topic when contributing to disease risk. We						
902	simulated four additional diseases to represent different structures (Supplementary Figure						
903	22).						
904	• Genetic effects interact with topic loading on altering disease risk. The interaction						
905	term is added to the mean of disease liability, which is sampled from a Gaussian						
906	distribution. The disease is then sampled by a threshold on the liability, where the						
907	incidence rate is by default 0.5. The interaction effect is varied from 0.4 to 4, with						
908	default value equal to 2.						
909	• Pleiotropy effects are simulated with a variant that have both genetic-disease and						
910	genetic-topic-disease effects. Both genetic and topic effects are added to the mean						
911	of disease liability. A disease is sampled by a threshold with default incidence rate						
912	equal to 0.5. The topic-disease effect is varied from 0.4 to 4, with default value						
913	equal to 2.						
914	• Pleiotropy effect with nonlinear topic-disease effect. A quadratic term of topic-						
915	disease effect added to the second model.						
916	• Pleiotropy effect with nonlinear genetic-disease effect. A quadratic term of						
917	genetic-disease effect added to the second model.						
918							
919	For disease-topic or topic-disease causal effects, we simulated 50 repetition at each causal effect						
920	size. For interaction analysis, we repeated 10 times at each parameter value, as there are more						
921	SNPs for uncertainty estimation. The simulated disease sets are fed into the inference procedure						
922	to infer the patient topic weights.						
923							
924							
925							
926							

It is made available under a CC-BY 4.0 International license .

927 Tables

Acronym	Disease systems	Representative diseases	Number of associated diseases
NRI	Neoplasms, respiratory, infectious diseases	Secondary malignancy of lymph nodes; Pneumococcal pneumonia; Bacterial infection NOS	53
CER	Circulatory system, endocrine/metabolic, respiratory	Type 2 diabetes; Obesity; Chronic airway obstruction	41
SRD	Sense organs, respiratory, dermatologic	Cataract; Septal Deviations/Turbinate Hypertrophy; Benign neoplasm of skin	38
CVD	Cardiovascular disease	Hypercholesterolemia; Coronary atherosclerosis; Myocardial infarction	27
UGI	Upper gastrointestinal disease	Diaphragmatic hernia; Benign neoplasm of other parts of digestive system; Gastritis and duodenitis;	22
LGI	Lower gastrointestinal disease	Irritable Bowel Syndrome; Benign neoplasm of colon; Anal and rectal polyp;	13
FGND	Female genitourinary, neoplasms, digestive	Uterine leiomyoma; Malignant neoplasm of female breast; Hypothyroidism NOS	34
MGND	Male genitourinary, neoplasms, digestive	Urinary tract infection; Cancer of prostate; Other disorders of bladder	33
MDS	Musculoskeletal, digestive, symptoms	Back pain; Cholelithiasis; Other disorders of soft tissues	29
ARP	Arthropathy-related disease	Arthropathy NOS; Rheumatoid arthritis; Enthesopathy	26

It is made available under a CC-BY 4.0 International license .

- 930
- 931

932 Table 1. Summary of 10 inferred disease topics in the UK Biobank. For each topic, we list its

- 933 3-letter acronym, disease systems, representative diseases, and number of associated diseases
- 934 (defined as diseases with average diagnosis-specific topic probability >50% for that topic).
- Topics are ordered by the Phecode system (see Figure 3). 316 of 348 diseases analysed are
- associated with a topic; the remaining 32 diseases do not have a topic with average diagnosis-
- 937 specific topic probability >50%.
- 938
- 939

It is made available under a CC-BY 4.0 International license .



Figure 1: ATM provides an efficient way to represent longitudinal comorbidity data. Top
left: input consists of disease diagnoses as a function of age. Top right: ATM assigns a topic
weight to each patient. Bottom: ATM infers age-dependent topic loadings.

It is made available under a CC-BY 4.0 International license .



949

950 Figure 2: ATM outperforms LDA in simulations with age-dependent effects. In simulations 951 at different levels of age-dependent effects (left panels), we report the area under the precision and recall curve (AUPRC) for ATM vs. LDA as a function of subtype sample size proportion 952 (the proportion of diagnoses belonging to the smaller subtype) (right panels). Each dot represents 953 954 the mean of 100 simulations of 10,000 individuals. Error bars denote 95% confidence intervals. 955 (A) 20-year difference in age at diagnosis for the two subtypes. (B) 10-year difference in age at diagnosis for the two subtypes. (C) 5-year difference in age at diagnosis for the two subtypes. 956 Numerical results are reported in Supplementary Table 2. 957

It is made available under a CC-BY 4.0 International license .



959



963 systems, with alternating blue and red color for visualisation purposes; "Other" is a merge of five

964 Phecode systems: "congenital anomalies", "symptoms", "injuries & poisoning", "other tests",

and "death" (which is treated as an additional disease, see Methods). Topics are ordered by the

966 corresponding Phecode system. Further details on the 10 topics are provided in Table 1. Further

It is made available under a CC-BY 4.0 International license .

967 details on the diseases discussed in the text (type 2 diabetes and breast cancer) are provided in

968 Supplementary Figure 6. Numerical results are reported in Supplementary Table 4.

969





971

Figure 4. Topic loadings capture age-dependent comorbidities. (A) Age-dependent topic
loadings for two representative topics, CER and CVD; for each topic, we include the top seven
diseases with highest topic loadings. Results for all 10 topics are reported in Supplementary
Figure 13. (B) Box plot of disease topic loading as a function of rank; disease topic loadings are
computed as a weighted average across all values of age at diagnosis. (C) Box plot of patient
topic weight as a function of rank. Numerical results are reported in Supplementary Table 5.

It is made available under a CC-BY 4.0 International license .



981 Figure 5. Polygenic risk scores vary across disease subtypes defined by distinct topics. (A) 982 Stacked barplots of age-dependent subtypes (defined by topics) for 4 representative diseases 983 (type 2 diabetes, asthma, hypercholesterolemia, and essential hypertension); for each disease, we 984 include all subtypes with at least one diagnosis. Results for all 52 diseases are reported in Supplementary Figure 16. (B) Standardised excess PRS values in disease cases (s.d. increase in 985 PRS per unit increase in patient topic weight) for 4 representative diseases and 4 corresponding 986 987 topics. (C) Relative risk for cases of type 2 diabetes and hypercholesterolemia of CVD and 988 MGND subtypes (vs. controls) across PRS percentiles. Each point spans 2 PRS percentiles. 989 Lines denote regression on log scale. Error bars denote 95% confidence intervals. Numerical 990 results are reported in Supplementary Table 6.

It is made available under a CC-BY 4.0 International license .



992

Figure 6. Genetic correlations vary across disease subtypes defined by distinct topics. (a)
Excess genetic correlations for pairs of 15 disease subtypes or diseases (9 disease subtypes)
(denoted with asterisks) + 6 diseases without subtypes), relative to genetic correlations between

the underlying diseases. Full square with asterisk denotes FDR < 0.1; less than full squares have
area proportional to z-scores for difference. Grey squares denote NA (pair of diseases without
subtypes or pair of same disease subtype or disease). (b) Genetic correlations between the

- underlying diseases. Full circle denotes |z-score| > 4 for nonzero genetic correlation; less than
 full circles have area proportional to |z-score|. Numerical results are reported in Supplementary
- 1001 Table 9.

It is made available under a CC-BY 4.0 International license .



1003

1004 Figure 7. Examples of SNP x topic interaction effects on disease phenotypes. For each 1005 example, we report main SNP effects (log odds ratios) specific to each quartile of topic weights 1006 across individuals, for both the focal SNP (blue dots) and background SNPs for that disease and topic (genome-wide significant main effect ($P < 5 \times 10^{-8}$) but non-significant SNP x topic 1007 interaction effect (P > 0.05); grey dots). Dashed red lines denote aggregate main SNP effects for 1008 1009 each focal SNP. Error bars denote 95% confidence intervals. Grey lines denote linear regression 1010 of grey dots, with grey shading denoting corresponding 95% confidence intervals. Numerical results are reported in Supplementary Table 14. 1011 1012

It is made available under a CC-BY 4.0 International license .

1013 References

- Abul-Husn, N. S. & Kenny, E. E. Personalized Medicine and the Power of Electronic Health
 Records. *Cell* **177**, 58–69 (2019).
- 1016 2. Bulik-Sullivan, B. et al. An atlas of genetic correlations across human diseases and traits.
- 1017 *Nat. Genet.* **47**, 1236–1241 (2015).
- 1018 3. Wang, K., Gaitsch, H., Poon, H., Cox, N. J. & Rzhetsky, A. Classification of common
- 1019 human diseases derived from shared genetic and environmental determinants. *Nat. Genet.*
- **49**, 1319–1325 (2017).
- 1021 4. Zhao, W. et al. Identification of new susceptibility loci for type 2 diabetes and shared
- 1022 etiological pathways with coronary heart disease. *Nat. Genet.* **49**, 1450–1457 (2017).
- 1023 5. Zhu, Z. et al. A genome-wide cross-trait analysis from UK Biobank highlights the shared
- 1024 genetic architecture of asthma and allergic diseases. *Nat. Genet.* **50**, 857–864 (2018).
- Turley, P. *et al.* Multi-trait analysis of genome-wide association summary statistics using
 MTAG. *Nat. Genet.* **50**, 229–237 (2018).
- 1027 7. O'Connor, L. J. & Price, A. L. Distinguishing genetic correlation from causation across 52
 1028 diseases and complex traits. *Nat. Genet.* **50**, 1728–1734 (2018).
- 1029 8. Cortes, A., Albers, P. K., Dendrou, C. A., Fugger, L. & McVean, G. Identifying cross-
- disease components of genetic risk across hospital data in the UK Biobank. *Nat. Genet.* 52,
 1031 126–134 (2019).
- Morrison, J., Knoblauch, N., Marcus, J. H., Stephens, M. & He, X. Mendelian randomization
 accounting for correlated and uncorrelated pleiotropic effects using genome-wide summary
 statistics. *Nat. Genet.* 52, 740–747 (2020).
- 1035 10. Peyrot, W. J. & Price, A. L. Identifying loci with different allele frequencies among cases of 1036 eight psychiatric disorders using CC-GWAS. *Nat. Genet.* **53**, 445–454 (2021).
- 1037 11. Mattheisen, M. et al. Identification of shared and differentiating genetic architecture for

It is made available under a CC-BY 4.0 International license .

- 1038 autism spectrum disorder, attention-deficit hyperactivity disorder and case subgroups. *Nat.*
- 1039 *Genet.* **54**, 1470–1478 (2022).
- 1040 12. Cortes, A. et al. Bayesian analysis of genetic association across tree-structured routine
- 1041 healthcare data in the UK Biobank. *Nat. Genet.* **49**, 1311–1318 (2017).
- 1042 13. Zhang, H. et al. Genome-wide association study identifies 32 novel breast cancer
- 1043 susceptibility loci from overall and subtype-specific analyses. *Nat. Genet.* **52**, 572–581
- 1044 (2020).
- 1045 14. Mansour Aly, D. et al. Genome-wide association analyses highlight etiological differences
- 1046 underlying newly defined subtypes of diabetes. *Nat. Genet.* **53**, 1534–1542 (2021).
- 1047 15. Hautakangas, H. *et al.* Genome-wide analysis of 102,084 migraine cases identifies 123 risk

1048 loci and subtype-specific risk alleles. *Nat. Genet.* **54**, 152–160 (2022).

- 1049 16. Srebro, N. & Shraibman, A. Rank, Trace-Norm and Max-Norm. in Learning Theory 545–
- 1050 560 (Springer Berlin Heidelberg, 2005).
- 1051 17. Candès, E. & Recht, B. Exact matrix completion via convex optimization. *Commun. ACM*1052 55, 111–119 (2012).
- 1053 18. Yan, J. & Pollefeys, M. A General Framework for Motion Segmentation: Independent,
- Articulated, Rigid, Non-rigid, Degenerate and Non-degenerate. in *Computer Vision ECCV* 2006 94–106 (Springer Berlin Heidelberg, 2006).
- 1056 19. Ma, Y., Derksen, H. & Hong, W. Segmentation of multivariate mixed data via Lossy data
 1057 coding and compression. *IEEE Trans. Pattern Anal. Mach. Intell.* **29**, 1546–1562 (2007).
- 1058 20. Rao, S., Tron, R., Vidal, R. & Ma, Y. Motion segmentation in the presence of outlying,
- 1059 incomplete, or corrupted trajectories. *IEEE Trans. Pattern Anal. Mach. Intell.* 32, 1832–
 1060 1845 (2010).
- 1061 21. Liu, G. & Yan, S. Latent Low-Rank Representation for subspace segmentation and feature
- 1062 extraction. in 2011 International Conference on Computer Vision 1615–1622
- 1063 (ieeexplore.ieee.org, 2011).

It is made available under a CC-BY 4.0 International license .

- 1064 22. Liu, Z. *et al.* Efficient Low-rank Multimodal Fusion with Modality-Specific Factors. *arXiv*1065 [*cs.Al*] (2018).
- 1066 23. Chen, Y. & Chi, Y. Harnessing Structures in Big Data via Guaranteed Low-Rank Matrix
- 1067 Estimation: Recent Theory and Fast Algorithms via Convex and Nonconvex Optimization.
- 1068 *IEEE Signal Process. Mag.* **35**, 14–31 (2018).
- 1069 24. Chen, Y. & Candès, E. J. The projected power method: An efficient algorithm for joint
- 1070 alignment from pairwise differences. *Commun. Pure Appl. Math.* **71**, 1648–1714 (2018).
- 1071 25. Jia, G. *et al.* Estimating heritability and genetic correlations from large health datasets in the
- absence of genetic data. *Nat. Commun.* **10**, 1–11 (2019).
- 1073 26. Tanigawa, Y. *et al.* Components of genetic associations across 2,138 phenotypes in the UK
- 1074 Biobank highlight adipocyte biology. *Nat. Commun.* **10**, 4064 (2019).
- 1075 27. Sakaue, S. et al. A cross-population atlas of genetic associations for 220 human
- 1076 phenotypes. *Nat. Genet.* **53**, 1415–1424 (2021).
- 1077 28. Jia, G. *et al.* Discerning asthma endotypes through comorbidity mapping. *Nat. Commun.*1078 **13**, 1–19 (2022).
- 1079 29. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.
 1080 *Nature* 562, 203–209 (2018).
- 1081 30. of Us Research Program, A. The 'All of Us' Research Program. *N. Engl. J. Med.* 381, 668–
 1082 676 (2019).
- 1083 31. Ishigaki, K. *et al.* Large-scale genome-wide association study in a Japanese population
- identifies novel susceptibility loci across different diseases. *Nat. Genet.* 52, 669–679
 (2020).
- 1086 32. Siggaard, T. et al. Disease trajectory browser for exploring temporal, population-wide
- 1087 disease progression patterns in 7.2 million Danish patients. *Nat. Commun.* **11**, 1–10 (2020).
- 1088 33. Posey, J. E. *et al.* Resolution of Disease Phenotypes Resulting from Multilocus Genomic
- 1089 Variation. *N. Engl. J. Med.* **376**, 21–31 (2017).

- 1090 34. Cook, E. K. *et al.* Comorbid and inflammatory characteristics of genetic subtypes of clonal
 1091 hematopoiesis. *Blood Adv* 3, 2482–2486 (2019).
- 1092 35. Udler, M. S. et al. Type 2 diabetes genetic loci informed by multi-trait associations point to
- 1093 disease mechanisms and subtypes: A soft clustering analysis. *PLoS Med.* **15**, e1002654
- 1094 (2018).
- 36. Wani, B., Aziz, S. A., Ganaie, M. A. & Mir, M. H. Metabolic Syndrome and Breast Cancer
 Risk. *Indian J. Med. Paediatr. Oncol.* 38, 434–439 (2017).
- 1097 37. Blei, Ng & Jordan. Latent dirichlet allocation. J. Mach. Learn. Res. (2003).
- 1098 38. Pritchard, J. K., Stephens, M. & Donnelly, P. Inference of population structure using
- 1099 multilocus genotype data. *Genetics* **155**, 945–959 (2000).
- 1100 39. Bishop, C. M. Pattern Recognition and Machine Learning. (Springer New York, 2006).
- 40. Teh, Y., Newman, D. & Welling, M. A collapsed variational Bayesian inference algorithm for
 latent Dirichlet allocation. *Adv. Neural Inf. Process. Syst.* **19**, (2006).
- 41. Grau, J., Grosse, I. & Keilwagen, J. PRROC: computing and visualizing precision-recall and
 receiver operating characteristic curves in R. *Bioinformatics* **31**, 2595–2597 (2015).
- 42. Wu, P. *et al.* Mapping ICD-10 and ICD-10-CM Codes to Phecodes: Workflow Development
 and Initial Evaluation. *JMIR Med Inform* 7, e14325 (2019).
- 1107 43. Suvila, K. *et al.* Early Onset Hypertension Is Associated With Hypertensive End-Organ
- 1108 Damage Already by MidLife. *Hypertension* HYPERTENSIONAHA11913069 (2019).
- 1109 44. Wong, B. et al. Cardiovascular Disease Risk Associated With Familial
- 1110 Hypercholesterolemia: A Systematic Review of the Literature. *Clin. Ther.* **38**, 1696–17091111 (2016).
- 45. Shah, M. S. & Brownlee, M. Molecular and Cellular Mechanisms of Cardiovascular
 Disorders in Diabetes. *Circ. Res.* **118**, 1808–1829 (2016).
- 1114 46. Shah, A. D. *et al.* Type 2 diabetes and incidence of cardiovascular diseases: a cohort study
- 1115 in 1.9 million people. *The Lancet Diabetes & Endocrinology* **3**, 105–113 (2015).

It is made available under a CC-BY 4.0 International license .

- 1116 47. Dabelea, D. & Hamman, R. F. Elevated Cardiometabolic Risk Profile Among Young Adults
- 1117 With Diabetes: Need for Action. *Diabetes care* vol. 42 1845–1846 (2019).
- 1118 48. Wong, J. L. & Evans, S. E. Bacterial Pneumonia in Patients with Cancer: Novel Risk
- 1119 Factors and Management. *Clin. Chest Med.* **38**, 263–277 (2017).
- 1120 49. Falstie-Jensen, A. M. et al. Incidence of hypothyroidism after treatment for breast cancer-
- a Danish matched cohort study. *Breast Cancer Res.* 22, 1–10 (2020).
- 1122 50. Loh, P.-R., Kichaev, G., Gazal, S., Schoech, A. P. & Price, A. L. Mixed-model association
- 1123 for biobank-scale datasets. *Nat. Genet.* **50**, 906–908 (2018).
- 1124 51. Loh, P.-R. *et al.* Efficient Bayesian mixed-model analysis increases association power in
- 1125 large cohorts. *Nat. Genet.* **47**, 284–290 (2015).
- Jiang, X., Holmes, C. & McVean, G. The impact of age on genetic risk for common
 diseases. *PLoS Genet.* **17**, e1009723 (2021).
- 1128 53. Weir, B. S. & Cockerham, C. C. ESTIMATING F-STATISTICS FOR THE ANALYSIS OF
- 1129 POPULATION STRUCTURE. *Evolution* **38**, 1358–1370 (1984).
- 1130 54. Bhatia, G., Patterson, N., Sankararaman, S. & Price, A. L. Estimating and interpreting FST:
- 1131 the impact of rare variants. *Genome Res.* **23**, 1514–1521 (2013).
- 1132 55. Scott, L. J. et al. A genome-wide association study of type 2 diabetes in Finns detects
- 1133 multiple susceptibility variants. *Science* **316**, 1341–1345 (2007).
- 1134 56. Maller, J. B. *et al.* Bayesian refinement of association signals for 14 loci in 3 common
- 1135 diseases. *Nat. Genet.* **44**, 1294–1301 (2012).
- 1136 57. Cheng, M., An, S. & Li, J. CDKN2B-AS may indirectly regulate coronary artery disease-
- 1137 associated genes via targeting miR-92a. Gene 629, 101–107 (2017).
- 1138 58. Scott, R. A. et al. An Expanded Genome-Wide Association Study of Type 2 Diabetes in
- 1139 Europeans. *Diabetes* **66**, 2888–2902 (2017).
- 1140 59. Aragam, K. G. *et al.* Discovery and systematic characterization of risk variants and genes
- 1141 for coronary artery disease in over a million participants. *bioRxiv* (2021)

It is made available under a CC-BY 4.0 International license .

doi:10.1101/2021.05.24.21257377.

1143 60. Indra, A. K. Epidermal TSLP: a trigger factor for pathogenesis of atopic dermatitis. *Expert*

1144 *Rev. Proteomics* **10**, 309–311 (2013).

- 1145 61. Kanai, M. *et al.* Genetic analysis of quantitative traits in the Japanese population links cell
- 1146 types to complex human diseases. *Nat. Genet.* **50**, 390–400 (2018).
- 1147 62. Oluwafemi, O. O. et al. Genome-Wide Association Studies of Conotruncal Heart Defects
- 1148 with Normally Related Great Vessels in the United States. *Genes* **12**, (2021).
- 1149 63. Blei, D. M. & Lafferty, J. D. A correlated topic model of Science. Ann. Appl. Stat. 1, 17–35
- 1150 (2007).
- 1151 64. Zaitlen, N. et al. Informed conditioning on clinical covariates increases power in case-

1152 control association studies. *PLoS Genet.* **8**, e1003032 (2012).

- 1153 65. Sun, B. B. *et al.* Genetic regulation of the human plasma proteome in 54,306 UK Biobank
 participants. *bioRxiv* 2022.06.17.496443 (2022) doi:10.1101/2022.06.17.496443.
- 1155 66. Mostafavi, H. *et al.* Variable prediction accuracy of polygenic scores within an ancestry
 1156 group. *Elife* 9, e48376 (2020).
- 1157 67. Dumitrescu, L. *et al.* Evidence for age as a modifier of genetic associations for lipid levels.
- 1158 Ann. Hum. Genet. **75**, 589–597 (2011).
- 1159 68. Chatterjee, N., Shi, J. & García-Closas, M. Developing and evaluating polygenic risk
- 1160 prediction models for stratified disease prevention. *Nat. Rev. Genet.* **17**, 392–406 (2016).
- 1161 69. Lin, J. et al. Integration of biomarker polygenic risk score improves prediction of coronary
- 1162 heart disease in UK Biobank and FinnGen. *bioRxiv* (2022)
- doi:10.1101/2022.08.22.22279057.
- 1164 70. Ghorbani, B., Javadi, H. & Montanari, A. An Instability in Variational Inference for Topic
- 1165 Models. in *Proceedings of the 36th International Conference on Machine Learning* (eds.
- 1166 Chaudhuri, K. & Salakhutdinov, R.) vol. 97 2221–2231 (PMLR, 09--15 Jun 2019).
- 1167 71. Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and richer

It is made available under a CC-BY 4.0 International license .

- 1168 datasets. *Gigascience* **4**, 7 (2015).
- 1169 72. International HapMap 3 Consortium *et al.* Integrating common and rare genetic variation in
- 1170 diverse human populations. *Nature* **467**, 52–58 (2010).